New advances in the management of juvenile idiopathic arthritis-2: The era of biologicals

被引：33

作者：

Beresford, M. W. ^{[1
]}

Baildam, E. M. ^{[2
]}

机构：

[1] Univ Liverpool, Alder Hey Childrens NHS Fdn Trust, Inst Child Hlth, Liverpool L12 2AP, Merseyside, England

[2] Alder Hey Childrens NHS Fdn Trust, Dept Rheumatol, Liverpool, Merseyside, England

来源：

ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION | 2009年 / 94卷 / 05期

关键词：

EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; ONSET STILL-DISEASE; RHEUMATOID-ARTHRITIS; ANAKINRA TREATMENT; OPEN-LABEL; ETANERCEPT TREATMENT; DOUBLE-BLIND; CHILDREN; METHOTREXATE; EFFICACY;

D O I：

10.1136/adc.2009.170860

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatic disease with significant long-term morbidity and mortality. Major advances have taken place in recent years in our understanding and the evidence base of JIA. The advent of biological therapies has opened a major new era in the medical management of JIA with recent trials published of etanercept, infliximab, adalimumab, abatacept, tocilizumab and anakinra. National and international collaborative clinical and research networks are ideally placed to enable future advances in the management of JIA and all paedatric rheumatic disorders. This review follows on from Part 1 of a review of recent advances in non-biological therapies in JIA, and focuses on the significant new advances in biological therapies in managing JIA.

引用

页码：151 / 156

页数：6

共 45 条

[1]

Brito BE, 1999, INVEST OPHTH VIS SCI, V40, P2583

[2] Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina [J].